Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03023254
Other study ID # PAP
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 6, 2017
Est. completion date July 20, 2020

Study information

Verified date April 2021
Source Pierre Fabre Dermo Cosmetique
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the benefit of the Avène hydrotherapy in subjects with pruritic plaque psoriasis


Description:

- To assess the benefit of the Avène hydrotherapy in subjects with pruritic plaque psoriasis in the: - Improvement of pruritus - Improvement of psoriasis severity - Improvement of quality of life - Change of pruritus and psoriasis biological markers - Intake/application of treatments and skin care products for psoriasis and pruritus management, evaluated during a follow-up period - To assess the time to pruritus relapse evaluated in subjects with pruritic plaque psoriasis, during the period following the Avène hydrotherapy (for the hydrotherapy group only) - To assess the global efficacy of the Avène hydrotherapy in pruritic plaque psoriasis, according to subjects' and investigators' opinion (for the hydrotherapy group only) - To assess the global cutaneous tolerance of the Avène hydrotherapy in subjects with pruritic plaque psoriasis (for the hydrotherapy group only)


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date July 20, 2020
Est. primary completion date July 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject with plaque psoriasis - Subject with moderate to very severe chronic pruritus whose NRS score = 4, (on a scale ranged from 0 to 10) - Subject with chronic pruritus, i.e. for at least 6 weeks, due to plaque psoriasis Exclusion Criteria: - Subject with erythrodermic psoriasis, pustular psoriasis or palmoplantar keratoderma - Subject with any other type of pruritus, not related to plaque psoriasis - Subject with an acute, chronic or progressive disease other than plaque psoriasis which could be the origin of the pruritus - Biotherapy, Phototherapy or PUVAtherapy treatment - Psoriasis treatment by LASER - Systemic or topical treatment taken/applied for psoriasis or pruritus management established or modified since the selection visit or planned to be established or modified between the inclusion visit and the end of the hydrotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Hydrotherapy
3-week Avène hydrotherapy

Locations

Country Name City State
France CHU Nord Service de Dermatologie Amiens
France CHU Angers Service de Dermatologie Angers
France Dr Martins-Hericher Angers
France CH de Boulogne sur Mer Hôpital DUCHENE - service de dermatologie Boulogne-sur-Mer
France CHU Morvan service de dermatologie Brest
France Dr Durbise Cahors
France Dr Parant Clisson
France Centre Hospitalier de Dunkerque - Service de Dermatologie Dunkerque
France Dr Abbadie Langon
France Dr Durieu Lavaur
France Dr Orsoni Limoges
France Dr Gutmann Heller Lingolsheim
France Dr Foucault Lorient
France Dr Nicol Marseille
France Dr Ruer-Mulard Martigues
France Hôpital St Eloi Service de Dermatologie Montpellier
France GHRMSA Hôpital Emile Muller Service de Dermatologie Mulhouse
France CHU Nantes - Unité Dermato-Cancérologie 7° nord Hotel Dieu Nantes
France Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD) - Hôpital l'Archet 2 Nice
France CHU Nice - Hôpital l'Archet 1 - Centre de recherche clinique Nice
France Dr Fritsch Obernai
France Dr Pfister Paris
France CHU de Poitiers Pole régional de cancérologie Service de dermatologie Poitiers
France Centre hospitalier Poissy St germain Saint-Germain-en-Laye
France Dr Gadroy Toulouse
France CHRU Tours Service de Dermatologie Tours
France Dr Abdo-Morales Tours
Spain Hospital de la Santa Creu i Sant Pau Dept. of Dermatology Barcelona
Spain Hospital Santa Caterina Girona

Sponsors (1)

Lead Sponsor Collaborator
Pierre Fabre Dermo Cosmetique

Countries where clinical trial is conducted

France,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pruritus clinical criterion Pruritus intensity assessed by the subject on the NRS from 0 to 10 Day18
Secondary Pruritus clinical criterion Pruritus intensity assessed by the subject on the NRS from 0 to 10 Day1
Secondary Pruritus clinical criterion Pruritus intensity assessed by the subject on the NRS from 0 to 10 Day111
Secondary Pruritus clinical criterion Pruritus intensity assessed by the subject on the NRS from 0 to 10 Day202
Secondary Psoriasis clinical criterion Psoriasis Area Severity Index assessed by the investigator on a scale ranged from 0 to 72 Day1, Day18, Day111 and Day202
Secondary Quality of life criterion ItchyQoL questionnaire Day1, Day18, Day111 and Day202
Secondary Biological criterion (markers linked to neurogenic inflammation, epidermal differentiation, inflammation, antimicrobial peptides) Psoriasis and pruritus biological markers Day1, Day18, Day111 and Day202
Secondary Hydrotherapy criterion Hydrotherapy global cutaneous tolerance on 4-point scale (0 = No effective ; 1=Little effective ; 2=Effective and 3=Very effective) Day18